1. Sweden Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
LIDDS AB (publ)

LIDDS AB (publ)

LIDDS.ST
LIDDS AB (publ)SE flagStockholm Stock Exchange
0.02
SEK
- -
- -
3.36MMarket Cap
LIDDS AB (publ)
LIDDS.ST
(Stockholm Stock Exchange)

Recent

price

0.02

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
TTM
FRC
- -
- -
- -
- -
- -
- -
- -
0.05
0.36
- -
0.01
0.1
0.05
- -
- -
- -
Revenue per Share
-0.17
-0.35
-0.37
-0.37
-0.5
-0.52
-0.35
-0.32
-0.85
-1.25
-1.12
-1.08
-1.07
-0.63
-0.04
-0.03
Basic EPS, GAAP
- -
- -
- -
-1.01
-1.02
-0.97
-0.85
-1.17
-1
-1.43
-1.08
-1.31
-1.06
-0.42
-0.04
-0.03
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
-0.14
-0.3
-0.33
-0.32
-0.45
-0.48
-0.3
-7.4
-7.34
-8.26
-8.31
-8.05
-9.13
-5.56
0.01
-0.01
Book Value per Share
0.93
1.55
0.65
0.29
1.17
0.91
0.65
0.61
0.96
0.16
0.97
0.94
-0.04
0.19
0.03
0.01
Tangible Book Value per Share
11
10
10
11
14
15
19
21
24
25
29
34
34
63
136
136
Basic Weighted Avg Shares
- -
- -
- -
- -
- -
- -
- -
1
9
- -
- -
4
2
- -
- -
- -
Sales/Revenue/Turnover
- -
- -
- -
- -
- -
- -
- -
-648.34
-240.72
- -
-9,369.57
-1,048.68
-1,939.51
- -
- -
- -
Operating Margin (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
1
- -
Depreciation Expense
-2
-3
-4
-4
-7
-8
-7
-7
-21
-31
-32
-37
-37
-40
-6
-4
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
-648.44
-239.17
- -
-9,372.17
-1,048.68
-1,952.33
- -
- -
- -
Profit Margin (%)
10
15
6
3
17
14
12
12
22
3
27
31
-3
12
5
1
Working Capital
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
LT Debt
59
72
69
75
96
100
113
15
29
16
43
49
15
14
5
1
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
-131.18
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Mar'25
Jun'25
Sep'25
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
136
136
136
Market Capitalization
13
9
9

Working Capital

FRC

•

in mil. unless spec.
Mar'25
Jun'25
Sep'25
Total Current Assets
5
3
2
Cash, Cash Equivalents & STI
5
2
2
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
2
1
- -
Payables & Accruals
- -
- -
- -
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
2.34%
8.87%
-67.24%
Free Cash Flow
- -
-18.89%
-79.14%
Net Income, GAAP
19.78%
-11.79%
-85.23%
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
-0.18
-0.11
-0.07
- -
-0.63
2024
- -
-0.02
-0.01
-0.01
-0.04
2025
-0.01
-0.01
-0.01
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
Similar Companies
Psyence Biomedical Ltd. (PBM)
Zenas BioPharma, Inc. (ZBIO)
Modern Technology Corp. (MODC)
Actuate Therapeutics Inc (ACTU)
HST Global, Inc. (HSTC)
Cibus, Inc. (CBUS)
Business
LIDDS AB (publ) (LIDDS.ST) is a Sweden-based biotechnology company that develops pharmaceutical products utilizing its proprietary NanoZolid technology platform for local, controlled, and sustained drug release to enhance treatment precision, boost local efficacy, and minimize systemic side effects, primarily targeting oncology and other diseases; core products in its pipeline include Liproca Depot, a NanoZolid-formulated 2-hydroxyflutamide (2-HOF) anti-androgen for localized prostate cancer treatment prior to radical therapies; Nanodotax, a NanoZolid-formulated docetaxel chemotherapeutic agent demonstrated safe and well-tolerated in phase I studies with positive immunological responses in solid tumors; and Nanoimod, a preclinical NanoZolid-formulated toll-like receptor 9 (TLR9) agonist agatolimod poised for phase Ib trials in multiple cancers combined with checkpoint inhibitors. The company, founded in 1999 and headquartered in Uppsala, Sweden, operates within the pharmaceuticals and biotechnology sector, focusing on reformulating existing drugs for improved outcomes at lower development costs and listed on Nasdaq First North Growth Market since 2014. LIDDS maintains geographic operations centered in Sweden with partnerships extending internationally, including a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. for an undisclosed oncology indication and a license agreement with Puheng Pharma for Liproca Depot in China; its intellectual property covers the NanoZolid technology and derived products until at least 2037, validated through clinical trials and collaborations. Recent developments encompass the January 2024 announcement and February 2024 completion of acquiring all shares in Noviga Research AB, a biotechnology firm developing cancer drug NOV202, establishing it as a wholly owned subsidiary to broaden its oncology pipeline; the May 2024 appointment of Mats Wiking as new CEO effective September 2024 amid management refresh; and a November 2025 agreement for a reverse takeover of Proport Invest AB (publ) to restructure operations.